- Investing.com
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Analyst Perspectives | Price targets range from $180 to $280, reflecting varied views on ResMed's ability to navigate challenges from GLP-1 drugs and increased competition |
Market Expansion | Delve into ResMed's strategic moves beyond sleep apnea, targeting insomnia and COPD markets to diversify revenue streams and offset potential market share losses |
Financial Resilience | Explore ResMed's impressive financial performance, with double-digit revenue growth and improved operating margins, despite challenges in gross margins |
Sleep Tech Dominance | ResMed's strong market position in sleep and respiratory care, driven by innovative products like AirSense 11, faces potential disruption from emerging GLP-1 drugs |
Metrics to compare | RMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRMDPeersSector | |
---|---|---|---|---|
P/E Ratio | 27.7x | −14.1x | −0.5x | |
PEG Ratio | 0.75 | −0.19 | 0.00 | |
Price / Book | 6.5x | 1.8x | 2.6x | |
Price / LTM Sales | 7.2x | 2.7x | 2.9x | |
Upside (Analyst Target) | 10.6% | 84.8% | 53.0% | |
Fair Value Upside | Unlock | −4.9% | 8.9% | Unlock |